Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Partial epilepsies; Tonic-clonic epilepsy
  • Focus Therapeutic Use
  • Acronyms OPUS
  • Sponsors Biogen

Most Recent Events

  • 14 Sep 2021 Results assessing the efficacy and safety of natalizumab as adjunctive therapy in drug-resistant focal epilepsy published in the Neurology
  • 01 May 2021 Results analyzing electronic diary (e-diary) in OPUS trial to explore the efficacy, safety, and tolerability of natalizumab as adjunctive therapy in adult participants with drug-resistant focal epilepsy, published in the Epilepsy and Behavior.
  • 17 Mar 2021 Results characterizing the ER relationship of natalizumab in focal epileptic patients presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top